Showing 5161-5170 of 5693 results for "".
- Understanding the Eye’s ‘Plumbing’ Could Lead to Future Treatments for Glaucoma, Other Diseaseshttps://modernod.com/news/understanding-the-eyes-plumbing-could-lead-to-future-treatments-for-glaucoma-other-diseases/2477092/Scientists in the University of Arizona Department of Physiology have identified a potential molecular mechanism that may hold the key to understanding how pressure is regulated in the eye. Funded by a $2.3 million 5-year grant from the National Institutes of Health (NIH) National Eye Inst
- Ocular Therapeutix Announces Strategic Update and Operational Restructuringhttps://modernod.com/news/ocular-therapeutix-announces-strategic-update-and-operational-restructuring/2477081/Ocular Therapeutix announced an operational restructuring plan that the company says is expected to result in an estimated $11 million in annualized savings through personnel reductions and approximately $14 million in one-time program deferrals. The company estimates that it will record costs as
- Optina Diagnostics and Wagner Macula Retina Center to Conduct a Study to Identify the Causes of Memory Loss Through Eye Diagnosticshttps://modernod.com/news/optina-diagnostics-and-wagner-macula-retina-center-will-collaborate-to-conduct-a-clinical-study-to-identify-the-causes-of-memory-loss-through-eye-diagnostics/2477076/Optina Diagnostics and Wagner Macula Retina Center are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina’s Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina’s future pivotal clinical trial. &
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-in-phase-2-study-conducted-in-japan/2477069/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork,
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Johnson & Johnson Vision Launches Tecnis Eyhance Monofocal IOL in Indiahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-eyhance-monofocal-iol-in-india/2477059/Johnson & Johnson Vision announced the launch of Tecnis Eyhance IOL, which is designed to extend depth of focus from distance to intermediate vision. Over the past several decades, India’s eye care system has made tremendous strides towards high q
- EyePrint Prosthetics Releases New Scleral Lens Technology: ScanFitPROhttps://modernod.com/news/eyeprint-prosthetics-releases-new-scleral-lens-technology-scanfitpro/2477058/EyePrint Prosthetics has announced the development of its new scleral lens fitting software, ScanFitPRO. This new technology simplifies every-day contact lens fitting by employing EyePrint Prosthetic’s scleral lens designer algorithm to automatically design a lens in 3-dimensional space, accordin
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random